Mitral valve prolapse in young healthy individuals. An early index of autoimmunity?
Article 2009 en
Authors
ME
Maria‐Eleftheria Evangelopoulos
ST
Savvas Toumanidis
DS
D Sotou
Abstract
1 min read
Mitral valve prolapse (MVP) is a benign valvular abnormality. However, an increased prevalence of MVP is reported in patients with systemic lupus erythematosus and autoimmune thyroid disease. Our aim was to evaluate whether the presence of MVP in healthy individuals might indicate a premature index of subclinical autoimmune disorder. A total of 75 individuals with MVP and 44 individuals without MVP were identified by echocardiography. Serum samples were examined for various organ and non-organ specific autoantibodies. In all, 35 of the 75 individuals with MVP had at least one autoantibody. ANA were detected in 17/75 in MVP(+) versus 1/44 in the MVP(-), (P < 0.05), and anti-ENA in 6/75 in the MVP(+) versus 0/44 in the control group, P = ns. In the MVP(+) group, thyroid autoantibodies, IgA and IgG RF were found at a statistically significant higher incidence, 16/75, 11/75 and 10/75 versus 1/44, 0/44 and 0/44 in the MVP(-)group, respectively (P < 0.05). The levels of IgG anticardiolipin antibodies were significantly higher in the MVP(+) group, P < 0.05. The presence of organ and non-organ specific autoantibodies in young healthy MVP(+) individuals insinuate the presence of subclinical autoimmunity and might suggest that autoimmune mechanisms might be involved in its pathogenesis. A follow-up of these individuals might elucidate whether MVP constitutes an early index of autoimmunity.
Francesca N. Delling, Jian Rong, Martin G. Larson, Birgitta T. Lehman, Deborah L. Fuller, Ewa Osypiuk, Plamen Stantchev, Brianne Hackman, Warren J. Manning, Emelia Benjamin, Robert A. Levine, Ramachandran S. Vasan
Irene Kaloumenou, George Mastorakos, Maria Alevizaki, Leonidas H. Duntas, Aimilia Mantzou, Charalambos Ladopoulos, Aristides Antoniou, Dimitrios Chiotis, Ioannis Papassotiriou, George Chrousos, Catherine Dacou‐Voutetakis
Discussion(0)
No comments yet. Be the first to comment.